# Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality

> **NCT07743047** · — · NOT_YET_RECRUITING · sponsor: **IRCCS San Raffaele** · enrollment: 65 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07743047
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743047, "Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*